An Isoform-Selective, Small-Molecule Inhibitor Targets the Autoregulatory Mechanism of p21-Activated Kinase  by Deacon, Sean W. et al.
Chemistry & Biology
ArticleAn Isoform-Selective, Small-Molecule Inhibitor
Targets the Autoregulatory Mechanism
of p21-Activated Kinase
Sean W. Deacon,1,2 Alexander Beeser,1,2,3 Jami A. Fukui,1 Ulrike E.E. Rennefahrt,1 Cynthia Myers,1 Jonathan Chernoff,1
and Jeffrey R. Peterson1,*
1Basic Sciences Division, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
2These authors contributed equally to this work.
3Present address: Division of Biology, Kansas State University, Manhattan, KS 66506, USA.
*Correspondence: jeffrey.peterson@fccc.edu
DOI 10.1016/j.chembiol.2008.03.005SUMMARY
Autoregulatory domains found within kinases may
provide more unique targets for chemical inhibitors
than the conserved ATP-binding pocket targeted
by most inhibitors. The kinase Pak1 contains an
autoinhibitory domain that suppresses the catalytic
activity of its kinase domain. Pak1 activators relieve
this autoinhibition and initiate conformational rear-
rangements and autophosphorylation events leading
to kinase activation. We developed a screen for allo-
steric inhibitors targeting Pak1 activation and identi-
fied the inhibitor IPA-3. Remarkably, preactivated
Pak1 is resistant to IPA-3. IPA-3 also inhibits activa-
tion of related Pak isoforms regulated by autoinhibi-
tion, but not more distantly related Paks, nor >200
other kinases tested. Pak1 inhibition by IPA-3 in live
cells supports a critical role for Pak in PDGF-stimu-
lated Erk activation. These studies illustrate an alter-
native strategy for kinase inhibition and introduce
a highly selective, cell-permeable chemical inhibitor
of Pak.
INTRODUCTION
Protein kinases are important therapeutic targets and are con-
sidered highly druggable owing to their conserved ATP-binding
pocket that can accommodate small molecules. However,
because of the evolutionary conservation of this pocket across
kinases, ATP-competitive inhibitors can inhibit large numbers
of other kinases in addition to their intended targets (Bain
et al., 2007; Karaman et al., 2008). Recently, it was demonstrated
that ATP-competitive inhibitors such as imatinib (Gleevec) can
achieve unusually high kinase selectivity by binding a less con-
served region adjacent to the ATP-binding pocket (Nagar
et al., 2002; Schindler et al., 2000), thus underscoring the idea
that inhibitor interactions with less conserved regions of a kinase
can provide opportunities for greater kinase selectivity. Indeed,
many kinases contain nonconserved sequence elements out-
side the kinase domain that mediate important facets of their
function such as localization, substrate recruitment, or the regu-322 Chemistry & Biology 15, 322–331, April 2008 ª2008 Elsevier Ltdlation of catalytic activity. Several kinases contain autoinhibitory
domains that bind and inhibit the activity of the catalytic domain
(Cheetham, 2004). We, and others, have proposed that proteins
regulated by autoinhibition may be susceptible to inhibition by
small molecules that perturb the conformational changes that
accompany relief of autoinhibition (Cheetham, 2004; Liu and
Gray, 2006; Peterson et al., 2004; Peterson and Golemis,
2004). The additional domains and conformational changes
that mediate kinase autoregulation may, therefore, provide novel
opportunities for more specific small-molecule inhibition than
ATP-competitive compounds.
Members of the p21-activated kinases (Paks) are one such
family that is subject to autoregulation. Group I Paks (Paks 1–3)
are regulated by autoinhibition that is relieved by binding to the
21 kDa GTP-binding proteins Rac and Cdc42. This distinct reg-
ulatory mechanism is not observed, however, in the more
distantly related group II Paks (Paks 4–6). However, Pak5 may
undergo autoinhibition mediated by an unrelated domain (Ching
et al., 2003). Autoinhibition of Pak1 is mediated by the formation
of an inactive homodimer in which the autoregulatory region of
one monomer binds and inhibits the catalytic domain of its part-
ner and vice versa (Lei et al., 2000; Parrini et al., 2002). One crit-
ical element of the autoregulatory region is the kinase-inhibitory
segment, which binds in the active site cleft and sequesters the
kinase activation loop in an inactive conformation (Lei et al.,
2000). Pak1 activation involves the local unfolding of the autoin-
hibitory domain caused by binding of Rac/Cdc42 to a partially
overlapping region, resulting in Pak1 monomer dissociation
and displacement of the inhibitory segment. Subsequent auto-
phosphorylation events at multiple sites along Pak1 stabilize
the catalytically competent, monomeric conformation (Chong
et al., 2001; Lei et al., 2000; Parrini et al., 2002). This multistep
activation cascade may offer additional opportunities for small-
molecule binding that could selectively inhibit group I Paks.
Increasing data implicate Pak1 in tumorigenesis and metasta-
sis (reviewed in Kumar et al., 2006). Thus, inhibitors of Pak1 have
been suggested as a novel oncologic therapy (Kumar et al.,
2006; Nheu et al., 2002). Although no highly selective inhibitors
of Pak1 have been reported, several compounds originally iden-
tified for their ability to target other kinases also inhibit Pak family
members (Eswaran et al., 2007; Nheu et al., 2002; Porchia et al.,
2007). Here we report the identification and characterization of a
highly selective, non-ATP-competitive inhibitor that targets theAll rights reserved
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how conformational rearrangements accompanying kinase acti-
vation can be exploited by compounds to achieve greater target
specificity, and introduces a selective reagent for Pak inhibition.
RESULTS
A Chemical Screen Identifies IPA-3
as an Inhibitor of Pak1
To identify inhibitors of Pak1 activation, we developed a high-
throughput assay measuring ATP hydrolysis as an indicator of
Pak1 catalytic activity. Recombinant, full-length Pak1 exhibited
an apparent molecular weight of130 kDa by gel-filtration chro-
matography (Figure 1A). SDS-PAGE analysis demonstrated the
appropriate monomer molecular weight of 60 kDa (Figure 1A,
inset), as expected for the inactive Pak1 homodimer (Lei et al.,
2000). Pak1 was incubated with individual compounds followed
by addition of recombinant Cdc42-GTPgS (hereafter simply
Cdc42) and myelin basic protein (MBP) as substrate (Figure 1A,
inset) in the presence of 10 mM ATP (Figure 1B). Following incu-
bation, nonhydrolyzed ATP was quantified using Kinase-Glo
(Koresawa and Okabe, 2004). Titrations of both Pak1 (Figure 1C)
and Cdc42 (Figure 1D) demonstrated that ATP hydrolysis was
strictly dependent on both Pak1 and Cdc42. These results dem-
onstrate that ATP hydrolysis measured in this assay is due to
Pak1 kinase activity and confirm that the recombinant Pak1
utilized in the screen is autoinhibited yet activatable by Cdc42
as expected.
This assay was used to screen 33,000 structurally diverse
small molecules in duplicate. Compounds inhibiting ATP hydro-
lysis by greater than three standard deviations below themean of
control reactions in both replicates were considered for further
analysis. Approximately 1% of the compounds tested met this
criterion. A secondary screen was then conducted on active
compounds to identify those that were potentially non-ATP com-
petitive. Individual compounds (10 mM) were incubated with
Pak1, Cdc42, and MBP in the presence of [g-32P]ATP and were
assayed for their ability to inhibit incorporation of [32P]phosphate
intoMBP. To reduce the detection of undesired ATP-competitive
inhibitors, reactionswere conducted in the presence of 1mMun-
labeled ATP. Of the 342 compounds identified in the primary
screen, 32 compounds continued to exhibit robust inhibition at
1 mM ATP. These compounds were ranked according to their
relative potency and reproducibility of inhibition in subsequent
assays, as well as their commercial availability. The cumulative
results of these secondary assays led us to focus on one
particular compound, 2,20-dihydroxy-1,10-dinaphthyldisulfide
(Figure 2A; hereafter called IPA-3), that at 10 mM inhibited
Pak1 activity by 95% ± 3%.
IPA-3 Is a Direct, Noncompetitive Inhibitor of Pak1
To determine the protein target of IPA-3, we performed Pak1
kinase assays in which MBP was omitted. Pak1 kinase activity
was measured by monitoring Pak1 autophosphorylation using
phospho-specific antibodies against threonine 423 within the
activation loop (Thr423; Zenke et al., 1999). IPA-3 (10 mM)
prevented Cdc42-stimulated Pak1 autophosphorylation on
Figure 1. An ATP Depletion Assay Reports
Cdc42-Dependent Pak1 Activation
(A) Recombinant Pak1 is a homodimer. The gel-
filtration elution profile of Pak1 is shown. Elution
volumes of standards are indicated. Inset: Coo-
massie-stained SDS-PAGE analysis of Pak1 and
other proteins used in the screen.
(B) Pak1 assay scheme. Pak1 is incubated with its
activator, GTPgS-charged Cdc42, and a sub-
strate, myelin basic protein (MBP), in the presence
of 10 mM ATP. Control kinase reactions (top) hy-
drolyze a substantial fraction of the starting ATP
resulting in low final ATP concentrations, whereas
inhibited reactions (bottom) do not. Residual ATP
is enzymatically converted to chemiluminescence
proportional to residual ATP.
(C) ATP hydrolysis is strictly Pak1-dependent.
Cdc42 was incubated with MBP, ATP, and the
indicated concentrations of Pak1. Residual ATP
levels were measured as in (B). Results are ex-
pressed as ATP hydrolyzed in arbitrary units
(normalized to the maximum ATP hydrolyzed) as
a function of Pak1 concentration. Data points
and error bars show mean and SEM of triplicate
wells. Circled point indicates Pak1 concentration
used in the screen.
(D) ATP hydrolysis by Pak1 is Cdc42-dependent.
ATP depletion was monitored in reactions as in
(C) except that the indicated concentrations of
Cdc42 were used. Circled point indicates Cdc42
concentration used in the screen.Chemistry & Biology 15, 322–331, April 2008 ª2008 Elsevier Ltd All rights reserved 323
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An Allosteric Inhibitor Targets Pak AutoregulationThr423 (Figure 2B, top), demonstrating that IPA-3 must target
either Cdc42 or Pak1. We next substituted Cdc42 with a distinct
Pak1 activator, the sphingolipid sphingosine (Bokoch et al.,
1998). IPA-3 also prevented sphingosine-dependent Pak1
autophosphorylation (Figure 2B, bottom panel). Together, these
assays demonstrate that Pak1 is the protein target of IPA-3.
Furthermore, the inhibition of Thr423 phosphorylation, which
is required for full activation of Pak1 (Zenke et al., 1999),
indicates that IPA-3 may inhibit a step in the Pak1 activation
process.
To confirm the chemical identity of the active compound, we
developed a novel chemical synthesis of IPA-3 (see Figure S1
in the Supplemental Data available with this article online). The
inhibitory activity of resynthesized IPA-3 was confirmed using
in vitro kinase assays (data not shown), demonstrating that
2,20-dihydroxy-1,10-dinaphthyldisulfide was indeed the agent
responsible for inhibition of Pak1 activity.
To determine the potency of IPA-3, kinase assays were per-
formed at a range of compound concentrations, yielding an
IC50 for IPA-3 of 2.5 mM (Figure 2C). A number of structurally re-
lated compoundswere also tested (Figure S2), yet none inhibited
Pak1 kinase activity as potently as IPA-3. A structural isomer of
IPA-3, 2-naphthalenol-6,60-dithiobis (Figure 2A, right), termed
PIR-3.5 (Pak1 inhibitor-related 3.5), displayed no inhibitory
activity toward Pak1 (Figure 2C), and was therefore chosen as a
negative-control compound for subsequent analyses.
The ability of IPA-3 to inhibit Pak1 activity at 1 mM ATP
(Figure 2C) suggested that this compound might be noncompet-
itive with ATP. Indeed, when tested at a range of ATP concentra-
tions, the inhibitory activity of IPA-3 was not decreased by
increasing concentrations of ATP (Figure 2D). These results
clearly demonstrate that Pak1 inhibition by IPA-3 is not compet-
itive with ATP.
IPA-3 Does Not Target Exposed Cysteine
Residues on Pak1
Cysteine-modifying agents that form mixed disulfides with pro-
tein targets have been shown to perturb the biological activity
of proteins (Rice et al., 1995). Therefore, initial experiments to de-
termine the mechanism of Pak1 inhibition by IPA-3 focused on
the role of the disulfide bond in IPA-3 (Figure 2A). We found that
IPA-3 inhibitory activitywasdramatically reduced in thepresence
of >1 mM of the reducing agent dithiothreitol (DTT) (Figure 3A).
We also found that addition of DTT could relieve inhibition of
Pak1 when added after IPA-3 (Figure 3B). Thus, IPA-3 inhibition
of Pak1 could be both prevented and reversed by 1 mM DTT.
The sensitivity of IPA-3 inhibition to DTT could be a result of re-
duction of IPA-3 itself or the reduction of an IPA-3-Pak1 adduct.
We first considered the possibility that IPA-3 formedmixed disul-
fideswith Pak1. Pak1 contains five cysteine residues, all of which
are found in the kinase domain. Computational analysis of crystal
structures of Pak1 kinase domain in both active (Lei et al., 2005)
and autoinhibited conformations (Lei et al., 2000) using UCSF
Chimera demonstrated that only two of those residues, Cys360
and Cys411, are surface exposed. To determine whether inhibi-
tion by IPA-3 could be a result of the formation of mixed disul-
fides with these cysteines, we mutated both residues to serine.
Like wild-type Pak1, the mutated Pak1 (Pak1-CS) exhibited
a basal level of kinase activity that was stimulated by addition
of Cdc42 (Figure 3C). Importantly, Pak1-CS was similarly in-
hibited by 10 mM IPA-3 compared to wild-type Pak1 (Figure 3C),
demonstrating that the mechanism of IPA-3 inhibition is not
through the formation of mixed disulfides with Cys360 or
Cys411. In addition, Pak1 migration in nonreducing SDS-PAGE
and size-exclusion chromatography was not affected by IPA-3,
ruling out IPA-3-mediated formation of Pak1multimers or aggre-
gates (not shown).
Figure 2. IPA-3 Is a Direct, Non-ATP-
Competitive Inhibitor of Pak1
(A) Structure of IPA-3 and an inactive relative,
PIR-3.5.
(B) IPA-3 directly inhibits Pak1 autophosphoryla-
tion. Pak1 was incubated with ATP and either
Cdc42 (top panels) or sphingosine (bottom panels)
in the presence of DMSO or 10 mM IPA-3. Samples
were probed using phospho-specific antibodies
against Pak1 Thr423. Data are representative of
three experiments.
(C) IPA-3 inhibits Pak1 kinase activity with low
micromolar potency. Pak1 was preincubated with
the indicated concentrations of IPA-3 or PIR-3.5.
Kinase reactions were started by addition of
Cdc42, MBP, and a mixture of 1 mM ATP and
[g-32P]ATP. Kinase activity is reported as phos-
phate incorporation ontoMBPexpressed as a ratio
to MBP phosphorylated in reactions in the pres-
ence of solvent alone (1% DMSO). Data are repre-
sented as the mean ± SEM. nR 3.
(D) IPA-3 is noncompetitive with ATP. Kinase
assays were performed as in (C) at the indicated
concentrations of ATP and IPA-3. n = 3.324 Chemistry & Biology 15, 322–331, April 2008 ª2008 Elsevier Ltd All rights reserved
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a solution of IPA-3 by absorption spectroscopy in the presence
of a range of DTT concentrations. We observed a dramatic
change in the absorption spectrum of IPA-3 at R1 mM DTT
(Figure 3D). Interestingly, chemically synthesized 1-mercapto-
2-hydroxynaphthalene (IPA-3R), the expected product of the
reduction of the disulfide in IPA-3, exhibited an absorption spec-
trum indistinguishable from that of IPA-3 in the presence of 1mM
DTT (Figure 3D). Furthermore, IPA-3R rapidly reoxidized into
IPA-3 under our buffer conditions (Figure 3D). Thus, the sensitiv-
ity of IPA-3 inhibition to DTT is likely due to direct reduction of the
IPA-3 disulfide, althoughwe cannot formally rule out the possibil-
ity that IPA-3 forms a DTT-sensitive adduct with residues other
than surface-exposed cysteines.
IPA-3 Targets the Pak1 Activation Mechanism
Pak1 activation is a multistep process involving the relief of auto-
inhibitory interactions and autophosphorylation at key residues
(Buchwald et al., 2001; Chong et al., 2001; Zenke et al., 1999).
IPA-3 inhibition of Thr423 autophosphorylation suggests that
IPA-3may inhibit steps in the Pak1 activationmechanism. To de-
termine the point in Pak1 activation at which IPA-3 may be act-
ing, a series of kinase assays were performed in which the order
of addition of reaction components was systematically varied.
Consistent with the results of the initial screen, when IPA-3
was added prior to Cdc42 and ATP, it significantly inhibited
Pak1 kinase activity (Figure 4A, condition A). When added to
Pak1 after incubation with Cdc42, but prior to the addition of
ATP, IPA-3 similarly inhibited Pak1 (Figure 4A, condition B). Fi-
nally, we tested the ability of IPA-3 to inhibit Pak1 when added
after both Cdc42 and ATP, when Pak1 is preactivated
(Figure 2B, 200). Strikingly, IPA-3 was much less effective at
inhibiting this preactivated Pak1 (Figure 4A, IPA-3, condition
C). In contrast, the ATP-competitive inhibitor staurosporine in-
hibited Pak1 kinase activity equally regardless of when it was
added (Figure 4A, Stauro). The requirement that IPA-3 be pres-
ent prior to Pak1 activation to be effective was also observed
for Pak1 activated by sphingosine (data not shown). These re-
sults demonstrate that IPA-3 is ineffective at inhibiting preacti-
vated Pak1. Moreover, the ability of IPA-3 to dramatically inhibit
Pak1 only when added prior to Pak1 autophosphorylation sug-
gests that IPA-3 inhibits a step in the Pak1 activation process.
The Conformation of Inhibitor-Bound Pak1
We hypothesized that IPA-3 might inhibit Pak1 activation by sta-
bilizing the autoinhibited Pak1 conformation. Indeed, conforma-
tional stabilization of the autoinhibitory domain of N-WASP,
which is structurally related to the autoinhibitory domain of
Pak1 (Kim et al., 2000; Lei et al., 2000), has been reported for
a small-molecule N-WASP inhibitor (Peterson et al., 2004). In ad-
dition, the symmetrical dimeric structure of IPA-3 suggests that
this compound might contact both Pak1 monomers within the
autoinhibited dimer. One important feature of the Pak1 autoinhi-
bited conformation is the folding of the activation loop (residues
408–428) into the catalytic site of the kinase (Lei et al., 2000),
thereby masking the activation loop and rendering Thr423
Figure 3. The Role of Disulfides in IPA-3-
Mediated Pak1 Inhibition
(A) IPA-3 activity is diminished in the presence of
the reducing agent DTT. IPA-3 (10 mM) was incu-
bated with the indicated concentrations of DTT,
followed by the addition of Pak1. Kinase activity
was determined as in Figure 2. n = 6.
(B) DTT relieves IPA-3-dependent inhibition of
Pak1 and restores Cdc42-mediated activation.
Pak1 was incubated with IPA-3 and divided into
vessels containing 0 or 1000 mM DTT, followed
by addition of Cdc42 where indicated. Samples
were subjected to kinase assays as in Figure 2.
Data are represented as the mean ± SEM. n = 3.
(C) Mutation of solvent-accessible cysteine resi-
dues in Pak1 to serine does not prevent inhibition
by IPA-3. Pak1-CS (Cys360 mutated to serine,
Cys411 mutated to serine) and wild-type Pak1
were preincubated with either DMSO or the indi-
cated compound. Kinase activity was determined
as in Figure 2, and was normalized to the maxi-
mum activity in the presence of solvent alone
(1% DMSO) and Cdc42. n = 5.
(D) Absorption spectroscopy suggests that the
disulfide bond in IPA-3 is sensitive to reduction
by DTT. Absorption spectra were recorded for
20 mM IPA-3 in the presence of 0 (thick trace) or
1000 mM (thin trace) DTT. A freshly prepared
solution (20 mM) of the reduced form of IPA-3,
IPA-3R (1-mercapto-2-hydroxynaphthalene), was
also analyzed either immediately (thin dotted
trace) or following a 15 min incubation on the
benchtop (thick dotted trace). Data are represen-
tative of multiple experiments.Chemistry & Biology 15, 322–331, April 2008 ª2008 Elsevier Ltd All rights reserved 325
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a large conformational change in the activation loop exposes
Thr423 to phosphorylation by other Pak1 monomers as well as
other kinases (King et al., 2000; Parrini et al., 2002; Zenke
et al., 1999). Thus, accessibility of Thr423 to phosphorylation
can be used to reveal whether the activation loop is in the
‘‘open’’ (active) or ‘‘closed’’ (inactive) conformation.We therefore
tested the ability of exogenous kinases to phosphorylate Thr423
in the presence of IPA-3. We have found that Pak5 can phos-
phorylate Thr423 of Pak1 in vitro but is itself insensitive to IPA-3
(see below). For this reason, Pak5 was chosen as the exogenous
kinase for this assay.
To ensure that at all Thr423 phosphorylation was mediated by
Pak5, we mutated the gatekeeper residue of Pak5 (methionine
523) to glycine according to the strategy pioneered by Shokat
and colleagues (Liu et al., 1998). This Pak5 ATP-binding pocket
mutant (Pak5-AM) can utilize the bulky ATP derivative N6-benzyl-
ATP (N6-ATP), whereas wild-type Pak1 cannot (Figure 4B, com-
pare lanes 3 and 5). In vitro kinase assays using N6-ATP revealed
that Pak5-AM phosphorylates Pak1 on Thr423, and that these
phosphorylation events were enhanced in the presence of sphin-
gosine (Figure4B, lanes5and6). Importantly, IPA-3didnotprevent
Pak1 phosphorylation byPak5-AMand, indeed, promoted Thr423
phosphorylation in the absence of sphingosine (Figure 4B, com-
pare lanes 5 and 7). Thus, IPA-3 does not stabilize the native auto-
inhibited conformation of Pak1 but instead promotes a conforma-
tion of Pak1 in which Thr423 is exposed. Similar results were
obtained using 3-phosphoinositide-dependent kinase 1 (PDK1),
another Thr423-directed kinase (King et al., 2000 Figure S3A).
That Thr423 can be phosphorylated by exogenous kinases but
not by Pak1 itself in the presence of IPA-3 suggested that phos-
phorylation of this residue by exogenous kinases might over-
come Pak1 inhibition by IPA-3. To test this, we took advantage
of the observation that the gatekeeper residue mutation in
Pak5-AM renders Pak5-AM sensitive to inhibition by the ATP-
competitive inhibitor 1NM-PP1, whereas wild-type Pak1 kinase
activity was unaffected (Figure S3B). We first incubated Pak1
with Pak5-AM and N6-ATP in the presence of sphingosine and
either DMSO or IPA-3. Next we added 1NM-PP1, MBP, and
a mixture of ATP and [g-32P]ATP to specifically measure Pak1
catalytic activity. Prephosphorylation of Pak1 with Pak5-AM
and N6-ATP led to a significant increase in Pak1 catalytic activity
(Figure 4C, lane 1 versus 2). However, Pak5-AM phosphorylation
of Pak1 did not overcome inhibition by IPA-3 (Figure 4C, lane 3).
Inhibition of MBP phosphorylation by IPA-3 is due to direct inhi-
bition of Pak1, as the Pak5-AM phosphorylation of Pak1 was not
affected by IPA-3 (Figure 4B, lanes 6 and 8). Together, these re-
sults demonstrate that in the presence of IPA-3, Pak1 adopts
a conformation in which Thr423 is exposed and therefore must
be distinct from the autoinhibited conformation. Nevertheless,
this conformation is catalytically inactive and cannot be reacti-
vated by phosphorylation by exogenous kinases. In addition,
these results demonstrate that a group II Pak (Pak5) can phos-
phorylate the activation loop of a group I Pak (Pak1) in vitro,
suggesting the possibility of regulatory crosstalk between the
two Pak groups.
IPA-3 Targets Group I Paks
The Pak1 autoregulatory strategy is conserved in all group I Paks
(Paks 1–3). By contrast, the group II Paks (Paks 4–6) do not con-
tain the inhibitory domain found in group I Paks, and are not
thought to undergo autoinhibition by the same mechanism. We
Figure 4. IPA-3 Targets the Pak1 Autoregu-
latory Mechanism
(A) IPA-3 inhibits Pak1 activation but does not in-
hibit preactivated Pak1. Pak1 was incubated with
components in the following order: condition
A: 10 mM compound, Cdc42 and ATP; condition
B: Cdc42, compound, ATP; condition C: Cdc42
and ATP, compound. After all incubations, kinase
reactions were initiated by addition of MBP and
[g-32P]ATP. Kinase activity is reported as in
Figure 2 and was normalized to reactions in the
presence of 1% DMSO and Cdc42 under condi-
tion A. nR 4.
(B) IPA-3 promotes the accessibility of Thr423 to
phosphorylation by exogenous kinases. Pak1
was incubated with the indicated compound
followed by addition of the ATP-binding pocket
mutant Pak5 (Pak5-AM), sphingosine, and ATP
or N6-benzyl-ATP (N6-ATP). Reactions were ana-
lyzed using phospho-specific antibodies against
Pak1 Thr423 or total Pak1. Data are representative
of three experiments.
(C) Exogenous phosphorylation of Thr423 does
not restore the kinase activity of IPA-3-inhibited
Pak1. Pak1was incubated as in (B) in the presence
of 125 mM sphingosine and N6-ATP. Postincuba-
tion, 2 mM 1NM-PP1 was added to inhibit Pak5-
AM, and kinase assays were conducted. Kinase
activity is reported as in Figure 2 and normalized
to the reaction in lane 2. Data are represented as
the mean ± SEM. n = 4.326 Chemistry & Biology 15, 322–331, April 2008 ª2008 Elsevier Ltd All rights reserved
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expected, full-length Paks 1–3 displayed basal levels of kinase
activity that were stimulated by the addition of Cdc42 (Figure 5A).
Dramatic inhibition of kinase activity in the presence 10 mM IPA-3
but not PIR-3.5 was observed for all three group I Paks, with the
strongest inhibition observed for Pak1 (Figure 5A).
We next tested the ability of IPA-3 to inhibit full-length Pak5
and Pak6 and a catalytic fragment of Pak4. Consistent with
Figure 5. IPA-3 Kinase Selectivity
(A) IPA-3 inhibits all group I Paks. Paks were incubated with 10 mM indicated
compound followed by addition of buffer or Cdc42, MBP, and a mixture of
1 mM ATP and [g-32P]ATP. Kinase activity is reported as in Figure 2. nR 3.
(B) IPA-3 is not an effective inhibitor of group II Paks. Purified Pak4 kinase do-
main or full-length Pak5 and Pak6 were tested in kinase reactions as described
in (A). nR 4.
(C) Distribution of IPA-3 inhibitory activity against recombinant kinases. Full-
length human kinases (214) were treated with 10 mM IPA-3 and subjected to
kinase assays. The histogram represents the number of kinases that displayed
the indicated mean percent inhibition compared to control reactions with-
out inhibitor in two independent experiments. Data are represented as the
mean ± SEM.Chemistry & Biologreports demonstrating that these kinases do not undergo auto-
inhibition or Rac/Cdc42-mediated activation (Abo et al., 1998;
Cau et al., 2001; Lee et al., 2002), the basal kinase activity of the
group II Paks was not stimulated by Cdc42 (Figure 5B). Impor-
tantly, the kinase activity of Paks 4–6 was not dramatically
inhibited by 10 mM IPA-3 (Figure 5B, IPA-3). Taken together,
these results demonstrate that IPA-3 exhibits selectivity for the
group I versus group II Paks.
Kinase Specificity of IPA-3
To determine the specificity of IPA-3 across a larger fraction of
the kinome, we tested the ability of this compound to inhibit 214
full-length human kinases using an assay that monitors phos-
phorylationofapeptidesubstrate (InvitrogenZ0-Lyte). IPA-3 (10mM)
significantly inhibited (R50% inhibition) only 9 of the kinases
tested (4% of total) (Figure 5C; Table S1). By comparison, the
broad-spectrum kinase inhibitor staurosporine, the highly selec-
tive Bcr-Abl inhibitor imatinib, and the receptor tyrosine kinase
inhibitor gefitinib inhibited (byR50%) 93%, 12%, and 21% of the
kinases tested, respectively (data not shown). AlthoughPak2 and
Pak3 were represented in the collection of kinases tested, they
were not significantly inhibited by IPA-3. This can be explained
by the fact that the recombinant Paks used in the Z0-Lyte assay
are preactivated and no longer responsive to Cdc42 (Figure S4).
It shouldbealsobenoted that 34of 214kinaseswere tested in the
presence of 1 mMDTT (see Table S1), conditions sufficient to re-
duce the IPA-3 disulfide. Nevertheless, these data demonstrate
the remarkable kinase specificity of IPA-3, and further support
the notion that this inhibitor acts on the unique regulatory cycle
of group I Paks.
IPA-3 Inhibits Pak1-Mediated Signaling In Vivo
Platelet-derived growth factor (PDGF) promotes Pak activation
in fibroblasts (Beeser et al., 2005). We therefore tested the ability
of IPA-3 to inhibit PDGF-stimulated Pak activation in mouse em-
bryonic fibroblasts. Both basal and PDGF-stimulated Pak activ-
ities were impeded by 30 mM IPA-3 as assessed by in-gel kinase
assay (Figure 6, upper panel, arrows). In contrast, the activity of
an unidentified40 kDa kinase was unaffected (upper panel, ar-
rowhead). Western blotting of the same lysates with group I-spe-
cific Pak antibodies showed that the increase in Pak apparent
molecular weight in control PDGF-stimulated cells, likely due
to Pak autophosphorylation, was also inhibited by IPA-3 (Fig-
ure 6, Total Pak). The inhibition of Pak’s apparent molecular
weight increase by IPA-3 in cells was also observed in vitro (Fig-
ure 2B, bottom panel), supporting a common inhibitory mecha-
nism. These data show that IPA-3 can inhibit activation of group
I Paks in cells. The need for higher concentrations of IPA-3 for
Pak inhibition in cells compared to in vitro is likely due to reduc-
tion of the IPA-3 disulfide bond in the reducing cytoplasmic en-
vironment. This would be expected to be counteracted by the
large, exchangeable reservoir of IPA-3 present in the nonreduc-
ing cell-culturemedium, thusmaintaining a sufficient intracellular
concentration of active compound.
To assess the effect of IPA-3 on signaling components up-
stream of Pak, the same cell lysates were analyzed using phos-
pho-specific antibodies against activated forms of the PDGF re-
ceptor and Akt. IPA-3 had little effect on these signaling events
upstream of Pak. By contrast, Erk activation by PDGF, whichy 15, 322–331, April 2008 ª2008 Elsevier Ltd All rights reserved 327
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2005; Tang et al., 1997), was strongly inhibited by IPA-3 (Fig-
ure 6). Interestingly, IPA-3 caused a slight elevation in basal
Erk activity even in the absence of PDGF, although this effect
was cell-type-dependent (data not shown). As expected, the
control compound PIR-3.5 did not inhibit Erk activation (Figure 6,
right panels). Thus, IPA-3 specifically and selectively inhibits
signaling events mediated by group I Paks.
DISCUSSION
The work presented here describes the identification of a highly
selective inhibitor of group I Pak kinases that achieves this selec-
tivity by targeting the distinct autoregulatory mechanism con-
served in group I Paks. That IPA-3 targets this regulatory mech-
anism and not the kinase active site directly is supported by the
following findings. First, the inhibition of Pak1 is noncompetitive
with respect to ATP. Second, IPA-3 targets the group I but not
group II Pak kinases, which share a highly conserved C-terminal
kinase domain but differ in their N-terminal regulatory sequence
elements. Third, IPA-3 inhibits activation of Pak1 by diverse
activators, but does not inhibit preactivated Pak1. Finally, IPA-3
does not prevent rearrangements of the activation loop that
Figure 6. IPA-3 Selectively Inhibits Pak1 Activation in Mammalian
Cells
Mouse embryonic fibroblasts were serum starved for 18 hr, followed by treat-
ment with 30 mM IPA-3, PIR-3.5 (right panels), or DMSO for 10 min. Cells were
stimulated with 10 mg/ml PDGF-BB for 5 min and lysed. Cell lysates were nor-
malized by protein concentration and probed with antibodies as described in
Experimental Procedures. Endogenous Pak kinase activity was observed by
in-gel kinase assay.328 Chemistry & Biology 15, 322–331, April 2008 ª2008 Elsevier Ltdresult in phosphorylation by exogenous kinases. One interpreta-
tion of these findings is that IPA-3 prevents Pak1 activation by
stabilizing an activation intermediate that is semi-open yet cata-
lytically inactive. A precise understanding of the molecular basis
of Pak1 inhibition by IPA-3, however, awaits detailed structural
studies.
A number of endogenous protein regulators of Pak1 kinase ac-
tivity have been reported that appear to target the Pak1 autore-
gulatory strategy. hPIP1 (Xia et al., 2001), CRIPak (Talukder et al.,
2006), and the tumor suppressor merlin (Kissil et al., 2003) have
all been shown independently to bind the Pak1 autoregulatory
region and inhibit kinase activity. CIB1 also binds this region
but, like Rac and Cdc42, promotes Pak1 activity rather than
inhibiting it (Leisner et al., 2005). These observations suggest
that modulation of the Pak1 autoregulatory domain may be
a physiologically relevant strategy for regulating catalytic activ-
ity. Therefore, it is conceivable that IPA-3 may bind and/or inhibit
Pak1 in a manner that mimics endogenous protein inhibitors.
As expected for an allosteric kinase inhibitor, kinase profiling
experiments revealed a high degree of kinase selectivity to
IPA-3 inhibition (Table S1). The lack of kinase domain sequence
similarity or functional overlap in IPA-3 kinase targets is not un-
expected for a compound targeting a nonconserved regulatory
mechanism. Indeed, specificity profiling of clinical kinase inhibi-
tors has shown that many selective compounds also target
seemingly unrelated kinases (Karaman et al., 2008). These ob-
servations emphasize the importance of broad kinase profiling
experiments in the characterization of kinase inhibitor selectivity.
To our knowledge, the profiling studies of IPA-3 reported here
(Table S1) describe the first chemical inhibitor of Pak1 that
achieves documented specificity comparable to that of the
clinically relevant kinase inhibitors imatinib and gefitinib.
Although IPA-3 represents a novel experimental reagent to in-
hibit Pak kinase activity, other groups have reported the use of
small molecules derived from known ATP-competitive kinase in-
hibitors to target Pak1 (Nheu et al., 2002; Porchia et al., 2007).
However, these inhibitors target a number of other kinases,
and their broader kinase selectivity has not been reported. An al-
ternative approach to inhibiting Pak kinase activity has been the
expression of recombinant fragments such as the Pak inhibitory
domain or catalytically inactive mutants of Pak1 that inhibit the
activity of endogenous Pak protein, although these may cause
unintended Pak-independent side effects (Thullberg et al.,
2007). By contrast, we show here that IPA-3 is Pak isoform se-
lective, cell permeable, and rapidly acting. As such, this com-
pound can serve as a distinct tool to elucidate Pak function in
cells and may facilitate the validation of Pak inhibitors as a thera-
peutic strategy.
The screening strategy used to identify IPA-3 relied on the use
of full-length Pak1 prepared under conditions that preserve the
native autoregulatory mechanism. This is in contrast to the dom-
inant paradigm in kinase-targeted screens of utilizing constitu-
tively active kinase or isolated kinase domains (Sebolt-Leopold
and English, 2006). These screens are biased toward inhibitors
targeting the active site and are restricted in their ability to exploit
sequence differences outside the catalytic domain. The results
presented here support the possibility that screens using full-
length kinase may provide unexpected opportunities for alloste-
ric inhibition. This strategy need not be restricted to kinases,All rights reserved
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proteins that undergo conformational regulation (Peterson and
Golemis, 2004). Indeed, for scaffolding proteins, conformational
inhibitors of this type may provide the only route to achieving
inhibition by small molecules.
SIGNIFICANCE
Lack of target specificity is amajor limitation of many widely
used kinase inhibitors. This results in part from the high de-
gree of evolutionary conservation in the ATP-binding pocket
targeted by these compounds across the human kinome.
Nonconserved regulatory elements found in some kinases
may offer unique targets formore selective kinase inhibition.
Here we test this hypothesis using the p21-activated kinase
1 and report the screening for and identification of a highly
selective, cell-permeable inhibitor that targets the Pak1 au-
toregulatory mechanism. Biochemical studies suggest that
IPA-3 may trap a transient intermediate step in Pak activa-
tion, because preactivated Pak1 is insensitive to IPA-3. In
addition, IPA-3-bound Pak1 exhibits some but not all struc-
tural features of the active conformation, and is catalytically
inactive. Critically, kinase specificity profiling studies reveal
an exceptional degree of kinase selectivity by IPA-3, consis-
tent with its targeting the unique Pak1 regulatory domain.
Furthermore, cell-based experiments using IPA-3 provide
evidence that Pak promotes mitogen-activated protein
kinase activation and illustrate selective inhibition of Pak in
live cells. Thus, kinase autoregulatory mechanisms provide
an alternative target for kinase inhibition by small molecules.
The widespread use of constitutively active, recombinant
kinase forms in kinase inhibitor screening programs likely
limits the identification of compounds acting by such novel
allosteric mechanisms. Our results suggest that screening
assays that recapitulate biologically important regulatory
mechanisms may reveal additional opportunities for selec-
tive kinase inhibition.
EXPERIMENTAL PROCEDURES
Protein Purification and Characterization
The following proteins were purified as described: Cdc42-GTPgS (Peterson
et al., 2001), Pak2 (Rennefahrt et al., 2007), Pak4 and Pak5 catalytic domains
(Eswaran et al., 2007), and full-length Pak1 (Rennefahrt et al., 2007). Full-length
Pak3 (Bagrodia et al., 1995) and Pak5 (Cotteret et al., 2003) were expressed in
HEK293 cells and immunopurified (see below). Full-length Pak6 (PV3502) was
purchased from Invitrogen. MBP was purchased (Sigma) or purified from
bovine brain acetone powder (Sigma) as described (Prowse et al., 2000).
Recombinant Pak1 was characterized by analytical gel-filtration chromatog-
raphy on a calibrated Superdex 200 10/300GL column. For the identification of
surface-exposed cysteine residues within Pak1, computational analysis
of crystal structures of Pak1 kinase domain in both active (Lei et al., 2005)
and autoinhibited conformations (Lei et al., 2000) was performed using the
MS/MS solvent accessibility module of UCSF Chimera (Pettersen et al., 2004).
Immunopurification of Pak3 and Pak5
HEK293 cells were transfected with 0.5 mg Pak3 or myc-Pak5 DNA using lipo-
some-mediated transfection (Lipofectamine 2000, Invitrogen). Forty-eight
hours posttransfection, cells were washed in ice-cold phosphate-buffered
saline (PBS) and lysed into lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride
(PMSF), and 10 mg/ml each of chymostatin, leupeptin, and pepstatin). Insolu-Chemistry & Biologyble material was removed by centrifugation at 12,000 3 g for 10 min at 4C.
Lysates were incubated with protein A agarose (Pierce) and either anti-Pak3
(Cell Signaling Technology) or anti-myc (Santa Cruz Biotechnology) for at least
2 hr at 4C. Precipitates were washed twice in lysis buffer and once in assay
buffer (50mMHEPES [pH 7.5], 25mMNaCl, 1.25mMMgCl2, 1.25mMMnCl2).
Chemical Compounds
The compound library consisted of 30,000 diverse compounds, largely con-
forming to Lipinski’s rules, obtained from ChemDiv and the Challenge Set,
Mechanistic Diversity Set, Natural Products Set, and Structural Diversity Set
provided by the Developmental Therapeutic Program (DTP) of the National
Cancer Institute. Compounds were stored as 5 mM DMSO stock solutions
(except for the Mechanistic Diversity Set compounds, which were stored at
0.5 mM) at 80C and were thawed immediately prior to use in a dessicator.
IPA-3 was resynthesized and characterized as described in the Supplemental
Experimental Procedures. PIR (Pak inhibitor-related) compounds were
provided as dry powder by the DTP.
High-Throughput Luminescence Assay for Inhibitors
of Pak1 Activation
Recombinant Pak1 (8 ml of a 50 mg/ml solution) in assay buffer was aliquotted
using a BioTek MicroFill into wells of columns 2–23 of a 384-well plate (Corn-
ing). Individual compounds were then added using disposable 384-pin poly-
propylene pin replicators (Genetix) to transfer 20 nl from compound stock
plates. Reactions were started by the addition of a solution (7 ml per well)
containing MBP (0.32 mg/ml), GTPgS-charged Cdc42 (2.9 mg/ml), and ATP
(21 mM) in assay buffer. Final reaction composition: 450 nM Pak1, 1.3 mM
Cdc42, 0.15 mg/ml MBP, 10 mM ATP, 0.1% DMSO, and library compounds
at 7 mM. Plates were incubated for 2 hr at 30C. Reactions were stopped
by the addition of an equal volume of Kinase-Glo reagent (Promega) and incu-
bated for 10 min at room temperature. Chemiluminescence was measured at
555 nm (20 nm emission slit) using a Cary Eclipse fluorescence spectropho-
tometer (Varian) equipped with a microplate carrier.
Compound stock plates were organized with library compounds in columns
3–22 (20 ml of a 5 mM solution in DMSO). Column 2 contained three wells of
2 mM staurosporine as positive controls and the remaining wells of column
2 contained DMSO as negative controls. Column 23 was empty and these
wells served as a ‘‘no-addition’’ control. All compound plates were screened
in duplicate.
Data analysis was conducted on a plate-by-plate basis in Microsoft Excel.
Mean and standard deviation of the luminescence intensity of all wells were
calculated. Wells containing compounds that resulted in luminescence
intensities greater than three standard deviations above the mean of control
samples in both replicate plates were considered hits.
In Vitro Kinase Assays
Pak1 (571 nM final) in assay buffer was mixed with DMSO or compound for
5 min at room temperature, followed by addition of 4 mM Cdc42 and 8.3 mM
MBP for an additional 5 min. Kinase reactions were started by addition of
unlabeled ATP and 1–10 mCi [g-32P]ATP per reaction for 10 min at 30C. Final
DMSO concentration was 1%. Kinase reactions were stopped on dry ice.
Under these conditions, MBP phosphorylation was linear with time.
Kinase assays for Figure 4 were carried out as follows. Condition A: Pak1
was incubated for 5 min at room temperature with compound followed by ad-
dition of 4 mM Cdc42 and ATP for 20 min at 30C. Condition B: Pak1 was in-
cubated with Cdc42 for 20 min at 30C, followed by addition of compound for
5 min. Condition C: Pak1 was incubated with Cdc42 and ATP for 20 min at
30C, followed by addition of compound for 5 min. These incubations were
followed by addition of 8.3 mM MBP and a mixture of ATP and [g-32P]ATP
for 10 min at 30C. Final conditions for all reactions were 1% DMSO, 1 mM
ATP, and 1–10 mCi [g-32P]ATP. Reaction products were analyzed by scintilla-
tion counting (Rennefahrt et al., 2007) or by phosphorimager analysis (Fujifilm).
Background counts from no kinase controls were subtracted from all values
(scintillation counting assays) and kinase activity was reported as phosphate
incorporation onto MBP expressed as a ratio to MBP phosphorylated in the
presence of solvent alone. Phosphorimager background values were defined
as the signal density of an area surrounding each individual phospho-MBP
band and were subtracted from the corresponding phospho-MBP band.15, 322–331, April 2008 ª2008 Elsevier Ltd All rights reserved 329
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Recombinant Pak1 (571 nM final) in assay buffer was incubated with either
DMSO or the indicated compound in DMSO (1% DMSO final). This mixture
was incubated for 5 min at room temperature followed by the addition of either
4 mM Cdc42-GTPgS or 50 mM sphingosine (Avanti Polar Lipids) for 5 min. Ki-
nase reactions were started by the addition of 1 mM ATP. Reactions were
stopped by addition of SDS sample buffer (62.5 mM Tris [pH 6.8], 70 mM
SDS, 100 mM DTT, 10% glycerol) and boiled at 95C for 5 min. Samples
were subjected to SDS-PAGE and western blotting analysis using phospho-
specific antibodies against the activation loop autophosphorylation site threo-
nine 423 (Cell Signaling Technology). Total Pak1 was detected with anti-Pak
antibodies (C19, Santa Cruz).
Spectral Analysis of IPA-3
IPA-3was diluted to 20 mM in 50mMTris (pH 8.0) containing the indicated con-
centration of DTT. Samples were vortexed and analyzed in a Cary 50 Bio spec-
trophotometer (Varian). IPA-3 spectral traces were background subtracted
from traces of buffer containing DMSO alone (0.1%). Individual traces were
normalized to 0 absorbance units at 600 nm.
The absorption spectrum of IPA-3R was obtained by preparing a fresh 20
mM DMSO stock from powder that was immediately diluted into degassed
50 mM Tris (pH 7.5) to 20 mM (0.1% DMSO). This sample was vortexed and
the spectrum was obtained as described above either immediately or after in-
cubation for 15 min on the benchtop.
Thr423 Accessibility Assay
Pak1 (571 nM) in assay buffer was incubated with compound and Pak5-AM
(692.5 nM final), ATP or N6-benzyl-ATP (25 mM; Axxora), and 125 mM sphingo-
sine or DMSO at 30C for 20 min. Samples were analyzed by immunoblot
analysis using antibodies against Pak1 phospho-Thr423.
For determination of Pak1 kinase activity, samples prepared as above
received DMSO or 2 mM 1NM-PP1 (Calbiochem) (3% final DMSO), 8.3 mM
MBP, and a mixture of ATP and [g-32P]ATP (25 mM). Samples were incubated
for 10 min at 30C. Pak1 kinase activity was determined via phosphorimager
analysis.
Dephosphorylation of Recombinant Pak2
To obtain inactive, dephosphorylated Pak2, 100 nM recombinant full-length
Pak2 was treated with 100 U l protein phosphatase (New England Biolabs)
for 30 min at 30C in assay buffer supplemented with 3.25 mMMnCl2. Dephos-
phorylation of Pak2 was confirmed by western blot using phospho-specific
antibodies against Pak T423. Phosphatase activity was inhibited by addition
of 50 mM NaVO4 and 1 mM b-glycerophosphate.
Z-Lyte Assay
The Z-Lyte assay was performed by Invitrogen. Percent inhibition was ex-
pressed as a ratio of phosphorylated product formed in the presence of 10 mM
IPA-3 compared to phosphorylated product formed in reactions containing
1%DMSO. Inhibition data reflect mean kinase inhibition from two independent
trials.
Cell Treatment with IPA-3
Mouse embryonic fibroblasts immortalized with SV40 large T antigen were
grown in DMEM + 10% serum. Cells at 60%–80% confluency were starved
for 18 hr in serum-free DMEM. Cells were pretreated with DMSO or 30 mM
compound for 10 min, followed by addition of PDGF-BB (10 ng/ml; Sigma)
for 5 min. Cells were washed in ice-cold PBS and lysed into Roberts buffer
(50 mM Tris [pH 8], 10% glycerol, 1 mM EDTA, 137 mM NaCl, 1% NP-40
plus aprotinin, 1 mM PMSF, 1 mM NaVO4). Insoluble material was removed
by centrifugation, and protein concentration was determined by BCA assay
(Pierce). Equal protein amounts were subjected to SDS-PAGE and western
blotting using anti-Pak1 (C19, Santa Cruz), anti-phospho-PDGFR (3161),
anti-phospho-Akt (9271), anti-phospho-ERK (9102) (Cell Signaling Technolo-
gies), and anti-ERK (V1141, Promega). In-gel kinase assays were performed
as described (Beeser et al., 2005) with MBP as substrate.
Additional methods can be found in the Supplemental Experimental
Procedures.330 Chemistry & Biology 15, 322–331, April 2008 ª2008 Elsevier LtdSUPPLEMENTAL DATA
Supplemental Data include four figures, one table, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at http://www.chembiol.com/cgi/content/full/15/4/322/DC1/.
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